检索结果-南通市图书馆

Safety of intrathecal injection of Wharton's jellyderived mesenchymal stem cells in amyotrophic lateral sclerosis therapy

引用

Neural Regeneration Research 2019年第2期14卷 313-318页

作者： Monika Barczewska Mariusz Grudniak Stanis?aw Maksymowicz Tomasz Siwek Tomasz O?dak Katarzyna Jezierska-Wo?niak Dominika G?adysz Wojciech Maksymowicz Department of Neurology and Neurosurgery School of Medicine Collegium Medicum-University of Warmia and Mazury in Olsztyn University Clinical Hospital in Olsztyn Instytut Terapii Komórkowych w Olsztynie(Cell Therapies Institute FamiCord Group) Polski Bank Komórek Macierzystych (PBKM FamiCord Group) Department of Psychology Clinical Logopedics and Social Science in Medicine Faculty of Health Sciences Collegium Medicum-University of Warmia and Mazury in Olsztyn Department of Neurology and Neurosurgery Laboratory of Regenerative Medicine School of Medicine Collegium Medicum-University of Warmia and Mazury in Olsztyn

Animal experiments have confirmed that mesenchymal stem cells can inhibit motor neuron apoptosis and inflammatory factor expression and increase neurotrophic factor expression. Therefore, mesenchymal stem cells have been shown to exhibit prospects in the treatment of amyotrophic lateral sclerosis. However, the safety of their clinical application needs to be validated. To investigate the safety of intrathecal injection of Wharton's jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy, 43 patients(16 females and 27 males, mean age of 57.3 years) received an average dose of 0.42 × 106 cells/kg through intrathecal administration at the cervical, thoracic or lumbar region depending on the clinical symptoms. There was a 2 month interval between two injections. The adverse events occurring during a 6-month treatment period were evaluated. No adverse events occurred. Headache occurred in one case only after first injection of stem cells. This suggests that intrathecal injection of Wharton's jelly-derived mesenchymal stem cells is well tolerated in patients with amyotrophic lateral sclerosis. This study was approved by the Bioethical Committee of School of Medicine, University of Warmia and Mazury in Olsztyn, Poland(approval No. 36/2014 and approval No. 8/2016). This study was registered with the ClinicalTrials.gov(identifier: NCT02881476)on August 29, 2016.

关键词： amyotrophic lateral sclerosis stem cells therapy intrathecal injections Wharton's jelly-derived mesenchymal stem cells adverse events safety cerebrospinal fluid neural regeneration

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：